Delayed Total Knee Replacement with Hylan G-F 20

Abstract

We retrospectively examined prospective data on the incidence and time to total knee replacement (TKR) in (1) patients with grade IV osteoarthritis (OA) treated with hylan G-F 20 from 1997 to 2010 (full cohort; 1,863 knees) and (2) a patient subset treated from 1997 to 2003 (original cohort; 1,187 knees) to determine any continued hylan G-F 20 influence on TKR delay. In both the cohorts, 25 to 28% knees underwent a TKR, with an average of 2.8 to 3.1 years occurring between hylan G-F 20 and surgery. Age was a significant predictor of time to TKR. Knee synovitis increased slightly with repeat courses; most cases considered mild or moderate. Survival analysis showed that TKR was delayed for > 7 years in 75% of 1,863 grade IV OA knees (1,342 patients) treated with hylan G-F 20 in an orthopedic practice. Consistent with our previous report (Waddell and Bricker, 2007), we show hylan G-F 20 continues to delay the need for TKR.

Keywords

hylan G-F 20 - knee - osteoarthritis - pain - total knee replacement

• References

• 1 Cheng YJ, Hootman JM, Murphy LB, Langmaid GA, Helmick CG ; Centers for Disease Control and Prevention (CDC). Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation --- United States, 2007-2009. MMWR Morb Mortal Wkly Rep 2010; 59 (39) 1261-1265
• 2 Bitton R. The economic burden of osteoarthritis. Am J Manag Care 2009; 15 (8, Suppl): S230-S235
• 3 Brault MW, Hootman J, Helmick CG, Theis KA, Armour BS ; Centers for Disease Control and Prevention (CDC). Prevalence and most common causes of disability among adults—United States, 2005. MMWR Morb Mortal Wkly Rep 2009; 58 (16) 421-426
• 4 Centers for Disease Control and Prevention. A national public health agenda for osteoarthritis 2010. Available at: http://www.cdc.gov/arthritis/docs/oaagenda.pdf . Accessed January 14, 2014
• 5 Synvisc^® (hylan G-F 20) prescribing information. Genzyme biosurgery. Available at: http://www.synviscone.com/∼/media/SynviscOneUS/Files/synvisc_PI.pdf . Accessed January 15, 2014
• 6 Synvisc-One^® (hylan G-F 20) Prescribing information. Genzyme biosurgery. Available at: http://synviscone.com/∼/media/SynviscOneUS/Files/Synvisc-OnePI-70240104.pdf . Accessed January 15, 2014
• 7 Euflexxa^® (1% sodium hyaluronate) Prescribing information. Ferring Pharmaceuticals. Available at: http://www.euflexxa.com/assets/euflexxa_physician-f87c5c8e9b6f9317c6cfd0b7df1b48c6.pdf . Accessed January 15, 2014
• 8 Hyalgan^® (sodium hyaluronate) Prescribing information. Sanofi-Aventis U S LLC. Available at: http://www.hyalgan.com/download/hyalgan_pi.pdf . Accessed January 15, 2014
• 9 Orthovisc^® (sodium hyaluronate) Prescribing information. Anika Pharmaceuticals
• 10 Supartz^® (sodium hyaluronate) Prescribing information. Seikagaku Corporation. Available at: http://supartzprofessional.com/docs/PackageInsert.pdf . Accessed January 15, 2014
• 11 Gel-One^® (cross-linked hyaluronate) Prescribing Information. Seikagaku Corporation. Available at: http://www.zimmer.com/content/pdf/en-US/Gel-One_Pkg_Insert_Final.pdf . Accessed January 15, 2014
• 12 Lee SC, Rha DW, Chang WH. Rapid analgesic onset of intra-articular hyaluronic acid with ketorolac in osteoarthritis of the knee. J Back Musculoskeletal Rehabil 2011; 24 (1) 31-38
• 13 de Campos GC, Rezende MU, Pailo AF, Frucchi R, Camargo OP. Adding triamcinolone improves viscosupplementation: a randomized clinical trial. Clin Orthop Relat Res 2013; 471 (2) 613-620
• 14 Waddell DD, Bricker DC. Total knee replacement delayed with Hylan G-F 20 use in patients with grade IV osteoarthritis. J Manag Care Pharm 2007; 13 (2) 113-121
• 15 Paxton EW, Furnes O, Namba RS, Inacio MC, Fenstad AM, Havelin LI. Comparison of the Norwegian knee arthroplasty register and a United States arthroplasty registry. J Bone Joint Surg Am 2011; 93 (Suppl. 03) 20-30
• 16 Healy WL, Della Valle CJ, Iorio R , et al. Complications of total knee arthroplasty: standardized list and definitions of the Knee Society. Clin Orthop Relat Res 2013; 471 (1) 215-220
• 17 Ryu YJ, Chun EM, Shim SS, Kim JS, Kim YH. Risk factors for pulmonary complications, including pulmonary embolism, after total knee arthroplasty (TKA) in elderly Koreans. Arch Gerontol Geriatr 2010; 51 (3) 299-303
• 18 Bosque Jr J, Coleman SI, Di Cesare P. Relationship between deep vein thrombosis and pulmonary embolism following THA and TKA. Orthopedics 2012; 35 (3) 228-233 , quiz 234–235
• 19 Levy YD, Hardwick ME, Copp SN, Rosen AS, Colwell Jr CW. Thrombosis incidence in unilateral vs. simultaneous bilateral total knee arthroplasty with compression device prophylaxis. J Arthroplasty 2013; 28 (3) 474-478
• 20 Watanabe H, Sekiya H, Kariya Y, Hoshino Y, Sugimoto H, Hayasaka S. The incidence of venous thromboembolism before and after total knee arthroplasty using 16-row multidetector computed tomography. J Arthroplasty 2011; 26 (8) 1488-1493
• 21 Chang RN, Kim JH, Lee H , et al. Cerebral fat embolism after bilateral total knee replacement arthroplasty -A case report-. Korean J Anesthesiol 2010; 59 (Suppl): S207-S210
• 22 Lee SC, Yoon JY, Nam CH, Kim TK, Jung KA, Lee DW. Cerebral fat embolism syndrome after simultaneous bilateral total knee arthroplasty: a case series. J Arthroplasty 2012; 27 (3) 409-414
• 23 Hash II TW, Maderazo AB, Haas SB, Saboeiro GR, Trost DW, Potter HG. Magnetic resonance angiography in the management of recurrent hemarthrosis after total knee arthroplasty. J Arthroplasty 2011; 26 (8) 1357-1361 , e1
• 24 Park JJ, Slover JD, Stuchin SA. Recurrent hemarthrosis in a hemophilic patient after revision total knee arthroplasty. Orthopedics 2010; 33 (10) 771
• 25 Seo JG, Moon YW, Park SH, Lee JH, Kang HM, Kim SM. A case-control study of spontaneous patellar fractures following primary total knee replacement. J Bone Joint Surg Br 2012; 94 (7) 908-913
• 26 Dalury DF, Jiranek WA. The incidence of heterotopic ossification after total knee arthroplasty. J Arthroplasty 2004; 19 (4) (Suppl. 01) 447-452
• 27 Thienpont E, Schmalzried T, Bellemans J. Ankylosis due to heterotopic ossification following primary total knee arthroplasty. Acta Orthop Belg 2006; 72 (4) 502-506
• 28 Jaiswal PK, Perera JR, Khan W, Rao SG. Treating stiffness after total knee arthroplasty: a technical note and preliminary results. Open Orthop J 2012; 6: 276-280
• 29 Beaver Jr WB, Fehring TK. Abductor dysfunction and related sciatic nerve palsy, a new complication of metal-on-metal arthroplasty. J Arthroplasty 2012; 27 (7) e13-e15
• 30 Mistry D, O'Meeghan C. Fate of the infrapatellar branch of the saphenous nerve post total knee arthroplasty. ANZ J Surg 2005; 75 (9) 822-824
• 31 Parvizi J, Pulido L, Slenker N, Macgibeny M, Purtill JJ, Rothman RH. Vascular injuries after total joint arthroplasty. J Arthroplasty 2008; 23 (8) 1115-1121
• 32 Balderi T, Mistraletti G, D'Angelo E, Carli F. Incidence of postoperative urinary retention (POUR) after joint arthroplasty and management using ultrasound-guided bladder catheterization. Minerva Anestesiol 2011; 77 (11) 1050-1057
• 33 Balderi T, Carli F. Urinary retention after total hip and knee arthroplasty. Minerva Anestesiol 2010; 76 (2) 120-130
• 34 Clement ND, Jenkins PJ, Brenkel IJ, Walmsley P. Predictors of mortality after total knee replacement: a ten-year survivorship analysis. J Bone Joint Surg Br 2012; 94 (2) 200-204
• 35 Jämsen E, Puolakka T, Eskelinen A , et al. Predictors of mortality following primary hip and knee replacement in the aged. A single-center analysis of 1,998 primary hip and knee replacements for primary osteoarthritis. Acta Orthop 2013; 84 (1) 44-53
• 36 Choong PF, Dowsey MM. The grand challenge–managing end-staged joint osteoarthritis. Front Surg 2014; 1: 9
• 37 Waddell D, Estey D, Bricker DC, Marsala A. Viscosupplementation under fluoroscopic control. Am J Med Sports 2001; 4: 237-241
• 38 Waddell D, Rein A, Panarites C, Coleman PM, Weiss C. Cost implications of introducing an alternative treatment for patients with osteoarthritis of the knee in a managed care setting. Am J Manag Care 2001; 7 (10) 981-991
• 39 Neustadt DH. Long-term efficacy and safety of intra-articular sodium hyaluronate (Hyalgan) in patients with osteoarthritis of the knee. Clin Exp Rheumatol 2003; 21 (3) 307-311
• 40 Whitman C, Allen D, Comadoll JL, Thomason HC, Oweida SJ. A retrospective study of Supartz and repeat treatment for osteoarthritis pain in the knee. J Manag Care Med 2010; 13 (1) 43-47
• 41 Turajane T, Amphansap T, Labpiboonpong V, Maungsiri S. Total knee replacement following repeated cycles of intra-articular sodium hyaluronate (500-730 Kda) in failed conservative treatment of knee osteoarthritis: a 54-month follow-up. J Med Assoc Thai 2009; 92 (Suppl. 06) S63-S68
• 42 Wang Y, Wluka AE, Simpson JA , et al. Body weight at early and middle adulthood, weight gain and persistent overweight from early adulthood are predictors of the risk of total knee and hip replacement for osteoarthritis. Rheumatology (Oxford) 2013; 52 (6) 1033-1041
• 43 Scale D, Wobig M, Wolpert W. Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Curr Ther Res 1994; 55 (3) 220-232
• 44 Chevalier X, Jerosch J, Goupille P , et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Ann Rheum Dis 2010; 69 (1) 113-119
• 45 Conrozier T, Jerosch J, Beks P , et al. Prospective, multi-centre, randomised evaluation of the safety and efficacy of five dosing regimens of viscosupplementation with hylan G-F 20 in patients with symptomatic tibio-femoral osteoarthritis: a pilot study. Arch Orthop Trauma Surg 2009; 129 (3) 417-423
• 46 Altman RD, Rosen JE, Bloch DA, Hatoum HT, Korner P. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial). Semin Arthritis Rheum 2009; 39 (1) 1-9
• 47 Altman RD, Moskowitz R ; Hyalgan Study Group. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. J Rheumatol 1998; 25 (11) 2203-2212
• 48 Carrabba MP, Paresce E, Angelini M, Re KA, Torchiana EEM, Perbellini A. The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion. Eur J Rheumatol Inflamm 1995; 15 (1) 25-31
• 49 Grecomoro G, Martorana U, Di Marco C. Intra-articular treatment with sodium hyaluronate in gonarthrosis: a controlled clinical trial versus placebo. Pharmatherapeutica 1987; 5 (2) 137-141
• 50 Huskisson EC, Donnelly S. Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatology (Oxford) 1999; 38 (7) 602-607
• 51 Lundsgaard C, Dufour N, Fallentin E, Winkel P, Gluud C. Intra-articular sodium hyaluronate 2 mL versus physiological saline 20 mL versus physiological saline 2 mL for painful knee osteoarthritis: a randomized clinical trial. Scand J Rheumatol 2008; 37 (2) 142-150
• 52 Strand V, Baraf HS, Lavin PT, Lim S, Hosokawa H. A multicenter, randomized controlled trial comparing a single intra-articular injection of Gel-200, a new cross-linked formulation of hyaluronic acid, to phosphate buffered saline for treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 2012; 20 (5) 350-356
• 53 Waddell DD, Bricker DC. Hylan G-F 20 tolerability with repeat treatment in a large orthopedic practice: a retrospective review. J Surg Orthop Adv 2006; 15 (1) 53-59
• 54 Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007; 89 (4) 780-785
• 55 Health care utilization and economic cost of musculoskeletal diseases. In: The Burden of Musculoskeletal Diseases in the United States. 2nd ed. . Rosemont, IL: American Academy of Orthopaedic Surgeons; 2011: 219-252
• 56 Ruiz Jr D, Koenig L, Dall TM , et al. The direct and indirect costs to society of treatment for end-stage knee osteoarthritis. J Bone Joint Surg Am 2013; 95 (16) 1473-1480